Sign in
CompletedPhase 2

IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])

Key facts

Who runs it
Transcend Therapeutics Inc.
Where
Ireland2 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
20 people enrolled
Started
13 Jun 2024
Ended
12 Aug 2025
Type of study
Interventional
Record updated
16 December 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Prior participation in trial number TT-TSND-201 (IMPACT-1)

Who cannot take part

  • Any significant change in social or medial history which would preclude participation in this study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the long-term efficacy of methylone in participants with PTSD.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A 52-Week, Open-Label Evaluation of the Long-term Efficacy and Safety of Single and Repeated Treatments with Methylone for the Treatment of PTSD IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])
Record updated
16 December 2024